Videos & Reports

Play Video

The second Proof-of-Concept study using INV043 API undertaken in October 2021 produced an unexpected result, according to Dr Andrew Stephens from Hudson Institute.

Video interview with Dr Andrew Stephens from Hudson Institute who explained why he’s excited about the inital Proof-of-Concept findings on Invion’s INV043 API and how the unique technology could be a new way to treat a range of cancers

About NDF Research: NDF is an independent equity research firm based in Sydney, Australia. It focuses on Life Science companies that are publicly traded on the Australian Securities Exchange (ASX), most of which are headquartered in Australia and New Zealand.